Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
about
Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice.Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity.Expression of a biologically active GFP-α(S1)-casein fusion protein in Lactococcus lactis.A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in miceLactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infectionsInactivation of the CovR/S virulence regulator impairs infection in an improved murine model of Streptococcus pyogenes naso-pharyngeal infectionThe AgI/II family adhesin AspA is required for respiratory infection by Streptococcus pyogenes.The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.Delivery of therapeutic proteins to the mucosa using genetically modified microflora.Therapeutic drug delivery by genetically modified Lactococcus lactis.Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme diseaseMucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.Moving forward: a mucosal vaccine against group A streptococcus.Development of vaccine delivery vehicles based on lactic acid bacteria.Critical Role of Antimicrobial Peptide Cathelicidin for Controlling Helicobacter pylori Survival and Infection.Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells.Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses.Immunogenicity of a divalent group A streptococcal vaccine.Recombinant Lactococcus lactis Expressing Haemagglutinin from a Polish Avian H5N1 Isolate and Its Immunological Effect in Preliminary Animal Trials.Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens.A new plasmid vector for DNA delivery using lactococci.Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis.High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus-expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein.Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice.Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B.Modulation of peanut-induced allergic immune responses by oral lactic acid bacteria-based vaccines in mice.
P2860
Q30952009-E45CC10B-A4C7-4218-A8BA-7DC774BC29C7Q33253260-D74D7DA4-A6DE-4E15-B08F-C8AB6FA9AFA5Q33676056-671860D7-8A07-44B2-80D7-7331995A5A68Q34205652-28A51795-60B1-459A-8D31-D107F777EEEDQ34260712-B4B4D7B5-8C08-4C3F-9A7D-619E03AD8B64Q34413457-4827A31D-EECD-4EA8-BAEF-E5A42280D84CQ34545911-2042AEFB-0B7B-4AE7-9E09-43D6E675FDF7Q34568182-B2A06E1E-1F6A-465A-8275-71C2FAC6F860Q34700515-A57649E4-F587-4CC3-BAC2-5046224DF29CQ34701483-5A609FC4-05CB-4189-9405-6B4E05E0B60EQ34832263-4DCE5F79-C652-47D5-B380-E9876FF8C2F5Q35142923-F4C6EB8C-BE68-4A35-B089-82E2A4A3762DQ35596025-EFBFA892-0122-449C-81A7-3B244E6EEF0CQ36316890-21DB4503-1C81-4F5C-B7F0-652251802D23Q36631447-6AD3CCDA-AE03-41E8-A5C9-BCF65F162958Q36898061-810201FF-B6EA-4142-9269-D853EC5877F1Q37111626-562C3466-112D-4196-A06F-0ADA93F45B29Q37471470-5FA9DC23-D118-43BC-9B61-6D99878F90D9Q37503248-EA5FFA18-598A-4801-8B73-4BEF1CCE0134Q37928954-D3574ABF-79BF-471A-BFB7-F0E96B433169Q38800391-FEAD00FE-94DD-431B-9558-5EB6B71514FFQ39108993-E73CEC7F-CE95-4681-8C3E-7EDD9BA9B622Q39565371-7884822F-504E-4D0A-BC4D-08FB3CDA7426Q40278264-C977B56F-38EE-42A4-964F-FECF22A7D8BDQ40283850-B9670BEE-5FFD-4A4A-B38C-CED50D357EDDQ40701445-79FE0327-6D0F-4034-BEEB-7E9FD3E56F6AQ41839546-D4C6ECEB-ACCF-44AC-B1EC-929BCF2DC541Q43176145-E8024D79-ADF1-4BCB-8315-2A765DD76EAFQ43827717-E2E7561D-9AFD-46EA-BF69-7FEE608300BEQ45361339-2C2EE2FF-C290-425F-A190-B69A1EB19C81Q45883861-B54A3B29-27BC-40D8-9A14-DE4EA6DC7ADDQ47768949-B86B486E-1C40-482F-A55C-8B210981FD14Q48006667-F7B03714-E9A4-48EF-9375-20871F63AAA4
P2860
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@ast
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@en
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@nl
type
label
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@ast
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@en
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@nl
prefLabel
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@ast
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@en
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@nl
P2093
P2860
P1476
Mucosal vaccine made from live ...... n with Streptococcus pyogenes.
@en
P2093
Bruce L Geller
Kevin F Jones
Praveen Mannam
P2860
P304
P356
10.1128/IAI.72.6.3444-3450.2004
P407
P577
2004-06-01T00:00:00Z